SI-BONE (SIBN) Set to Announce Quarterly Earnings on Tuesday

SI-BONE (NASDAQ:SIBN - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect SI-BONE to post earnings of ($0.22) per share for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.04. SI-BONE had a negative return on equity of 24.27% and a negative net margin of 27.10%. The company had revenue of $39.97 million for the quarter, compared to the consensus estimate of $38.95 million. During the same quarter in the prior year, the business earned ($0.30) EPS. On average, analysts expect SI-BONE to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SI-BONE Stock Up 6.7 %

Shares of SIBN traded up $0.92 during mid-day trading on Tuesday, reaching $14.55. The company's stock had a trading volume of 418,327 shares, compared to its average volume of 386,589. SI-BONE has a 12-month low of $11.76 and a 12-month high of $21.70. The stock has a market cap of $606.59 million, a PE ratio of -14.26 and a beta of 1.22. The company has a debt-to-equity ratio of 0.22, a current ratio of 9.17 and a quick ratio of 8.12. The company's 50 day moving average is $14.30 and its 200 day moving average is $14.30.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SIBN. Morgan Stanley decreased their target price on SI-BONE from $21.00 to $19.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC decreased their price objective on SI-BONE from $27.00 to $19.00 and set a "buy" rating for the company in a research report on Tuesday, August 6th. Finally, Truist Financial decreased their price objective on SI-BONE from $18.00 to $16.00 and set a "buy" rating for the company in a research report on Monday, October 14th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, SI-BONE presently has a consensus rating of "Buy" and a consensus price target of $22.67.

Insider Activity

In related news, insider Anthony J. Recupero sold 2,087 shares of SI-BONE stock in a transaction on Monday, August 19th. The stock was sold at an average price of $14.17, for a total value of $29,572.79. Following the transaction, the insider now owns 236,717 shares in the company, valued at approximately $3,354,279.89. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other SI-BONE news, insider Anthony J. Recupero sold 2,087 shares of the business's stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $14.17, for a total transaction of $29,572.79. Following the transaction, the insider now owns 236,717 shares in the company, valued at $3,354,279.89. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Anthony J. Recupero sold 3,305 shares of the business's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total value of $44,881.90. Following the transaction, the insider now owns 233,412 shares in the company, valued at approximately $3,169,734.96. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,676 shares of company stock valued at $344,967 over the last quarter. Company insiders own 3.90% of the company's stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.